Cancer/Tumor Profiling Market worth $35.94 billion by 2030, growing at a CAGR of 18.74% - Exclusive Report by 360iResearch

The "Cancer/Tumor Profiling Market by Technology (Immunoassays, In-Situ Hybridization, Mass Spectrometry), Biomarker Type (Genomic Biomarker, Protein Biomarker), Cancer Type, Application - Global Forecast 2024-2030" report has been added to 360iResearch.com's offering.

The Global Cancer/Tumor Profiling Market to grow from USD 10.79 billion in 2023 to USD 35.94 billion by 2030, at a CAGR of 18.74%.

Request a Free Sample Report @ https://www.360iresearch.com/library/intelligence/cancer-tumor-profiling?utm_source=openpr&utm_medium=referral&utm_campaign=sample

Cancer/tumor profiling is a laboratory method that analyzes specific proteins, genes, and other molecules in a tumor to provide information about any genetic or molecular changes, such as gene mutations. Tumor profiling is the technology that oncologists widely use to determine if the pathways of a patient's tumor match up with available targeted treatments. Accelerated use of biomarkers in the treatment of cancer patients and increasing preference for customized cancer treatments coupled with government and international organization's efforts to develop cancer diagnosis methods support the widespread use of cancer/tumor profiling technologies. On the other hand, high capital investment in cancer/tumor profiling tools and services and low biomarker discovery-to-approval ratio hinders market development. However, the spread of next-generation sequencing, tumor profiling improvements, and point-of-care cancer detection technology expansion is expected to surge their use in the coming years.

Cancer/tumor profiling market landscape in North America, the EU, GCC, and developed countries across the Asia-Pacific region are highly advanced due to prominent market players and well-established regulatory frameworks and initiatives launched by the governments to reduce cancer burden while improving patient care. Cancer profiling is gradually gaining prominence in developing economies worldwide as investments in cancer diagnostics continue to rise. According to the American Cancer Society, approximately 1.9 million new cancer cases are anticipated to be diagnosed in the United States in 2023, bolstering the need for cancer profiling. Northern and Western European countries observe considerably high use and availability of biomarker testing procedures, reflecting their higher investment in healthcare. Market players across countries are collaborating with technology providers in the United States and European countries and each other to contribute to deploying the advancement in cancer diagnosis, profiling, and treatment procedures. Furthermore, the ongoing campaigns and cancer awareness programs have highlighted the need for cancer/tumor profiling in Asian countries.

Market Segmentation & Coverage:

This research report categorizes the Cancer/Tumor Profiling Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Technology, market is studied across Immunoassays, In-Situ Hybridization, Mass Spectrometry, Microarrays, Next-Generation Sequencing, and Polymerase Chain Reaction. The Next-Generation Sequencing commanded largest market share of 24.62% in 2023, followed by Immunoassays.

Based on Biomarker Type, market is studied across Genomic Biomarker and Protein Biomarker. The Genomic Biomarker commanded largest market share of 61.32% in 2023, followed by Protein Biomarker.

Based on Cancer Type, market is studied across Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma Cancer, and Prostate Cancer. The Lung Cancer commanded largest market share of 22.57% in 2023, followed by Breast Cancer.

Based on Application, market is studied across Biomarker Discovery, Clinical Application, Diagnostics, Personalized Medicine, Prognostics, Research, Screening, and Treatment & Monitoring. The Diagnostics commanded largest market share of 22.11% in 2023, followed by Personalized Medicine.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 39.24% in 2023, followed by Europe, Middle East & Africa.

Inquire Before Buying @ https://www.360iresearch.com/library/intelligence/cancer-tumor-profiling?utm_source=openpr&utm_medium=referral&utm_campaign=inquire

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Cancer/Tumor Profiling Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in the Cancer/Tumor Profiling Market. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

Key Company Profiles:

The report delves into recent significant developments in the Cancer/Tumor Profiling Market, highlighting leading vendors and their innovative profiles. These include 4basecare Onco Solutions Private Limited, ACT Genomics Co., Ltd. by Prenetics Global Limited, Agendia, Inc., Agilent Technologies, Inc., BostonGene Corporation, Caris Life Sciences, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GENINUS Inc., Genomic Life, GenScript Biotech Corporation, Guardant Health, Inc., Hologic, Inc., HTG Molecular Diagnostics, Inc., Illumina, Inc., IMBdx, Inc., Laboratory Corporation of America Holdings, Lucence Health, Inc., Merck KGaA, NanoString Technologies, Inc., Neogenomics, Inc., Nonacus Limited, OncoDNA S.A., Oncompass Medicine Hungary Kft., Paragon Genomics, Inc., Personalis, Inc., Perthera, Inc., Predictive Oncology Inc., Strand Life Sciences, Sysmex Corporation, Takara Bio Inc., Tempus Labs Inc., and Thermo Fisher Scientific Inc..

Key Topics Covered:

1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
6. Cancer/Tumor Profiling Market, by Technology
7. Cancer/Tumor Profiling Market, by Biomarker Type
8. Cancer/Tumor Profiling Market, by Cancer Type
9. Cancer/Tumor Profiling Market, by Application
10. Americas Cancer/Tumor Profiling Market
11. Asia-Pacific Cancer/Tumor Profiling Market
12. Europe, Middle East & Africa Cancer/Tumor Profiling Market
13. Competitive Landscape
14. Competitive Portfolio

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Cancer/Tumor Profiling Market?
2. Which are the products/segments/applications/areas to invest in over the forecast period in the Cancer/Tumor Profiling Market?
3. What is the competitive strategic window for opportunities in the Cancer/Tumor Profiling Market?
4. What are the technology trends and regulatory frameworks in the Cancer/Tumor Profiling Market?
5. What is the market share of the leading vendors in the Cancer/Tumor Profiling Market?
6. What modes and strategic moves are considered suitable for entering the Cancer/Tumor Profiling Market?

Read More @ https://www.360iresearch.com/library/intelligence/cancer-tumor-profiling?utm_source=openpr&utm_medium=referral&utm_campaign=analyst

Contact 360iResearch

Mr. Ketan Rohom
Sales & Marketing,
Office No. 519, Nyati Empress,
Opposite Phoenix Market City,
Vimannagar, Pune, Maharashtra,
India - 411014.
sales@360iresearch.com
+1-530-264-8485
+91-922-607-7550

About 360iResearch

360iResearch is a market research and business consulting company headquartered in India, with clients and focus markets spanning the globe.

We are a dynamic, nimble company that believes in carving ambitious, purposeful goals and achieving them with the backing of our greatest asset - our people.

Quick on our feet, we have our ear to the ground when it comes to market intelligence and volatility. Our market intelligence is diligent, real-time and tailored to your needs, and arms you with all the insight that empowers strategic decision-making.

Our clientele encompasses about 80% of the Fortune Global 500, and leading consulting and research companies and academic institutions that rely on our expertise in compiling data in niche markets. Our meta-insights are intelligent, impactful and infinite, and translate into actionable data that support your quest for enhanced profitability, tapping into niche markets, and exploring new revenue opportunities.

This release was published on openPR.